Perlmutter Cancer Center

This is a phase 2 trial of selumetinib (AZD6244 hydrogen sulfate) in children with recurrent or refractory solid tumors, CNS tumors, non-Hodgkin lymphomas and histiocytic disorders harboring specific activating mutations that result in pathologic activation of the MAPK pathway. Patients will receive selumetinib (AZD6244 hydrogen sulfate) for 28-day cycles at the MTD and recommended Phase 2 dose (RP2D) of 25 mg/m2/dose BID. The primary aim of this trial will be to establish the objective response rate to selumetinib (AZD6244 hydrogen sulfate). While there will not be multiple pre-determined mutation-based cohorts, responses will be analyzed retrospectively with respect to specific MAPK pathway activating mutations.